Special items: Ovarian Cancer and Us blog best viewed in Firefox

Sunday, August 22, 2010

NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline

"Pazopanib is currently approved by the FDA to treat patients with advanced renal cell carcinoma. The research grant to NCCN will evaluate the effectiveness of pazopanib in solid tumors including renal, sarcoma, thyroid, neuroendocrine, and ovarian cancers."

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.